Scholarlink

Introduction <p>In advanced non-small cell lung cancer (NSCLC) with <i>EGFR</i> exon&#xa0;19 deletions or exon&#xa0;21 L858R substitution mutations (Ex19del/L858R), intravenous amivantamab is approved for first-line treatment with lazertinib, and second-line treatment with carboplatin-pemetrexed. Subcutaneous amivantamab demonstrated noninferior pharmacokinetics and comparable efficacy with improved safety outcomes versus intravenous amivantamab in the PALOMA-3 trial. Venous thromboembolism (VTE) was also reduced when combined with prophylactic anticoagulation. In the COCOON trial, an enhanced prophylactic dermatologic regimen with intravenous amivantamab plus lazertinib treatment lowered grade ≥ 2 dermatologic adverse events (AEs). There are no studies combining subcutaneous administration with supportive care advancements in diverse participants with <i>EGFR</i>-mutated NSCLC. COPERNICUS (NCT06667076), an open-label, phase&#xa0;2b study aims to evaluate the efficacy and safety of subcutaneous amivantamab with lazertinib (cohort&#xa0;1) or with chemotherapy (cohort&#xa0;2) while preventing and proactively managing VTE and dermatologic AEs in a multinational, clinically representative population with <i>EGFR</i>-mutated NSCLC.</p> Methods <p>Eligible participants are adults with <i>EGFR</i> Ex19del/L858R NSCLC. A pragmatic study approach will be used to eliminate potential barriers to enrollment and increase diversity. Cohort&#xa0;1 will enroll participants without prior systemic therapy to receive subcutaneous amivantamab and oral lazertinib. Cohort&#xa0;2 will enroll participants with disease progression on EGFR-tyrosine kinase inhibitors to receive subcutaneous amivantamab and chemotherapy (carboplatin-pemetrexed). Both cohorts will receive enhanced dermatologic management; cohort&#xa0;1 will receive prophylactic anticoagulation for the first 4&#xa0;months of treatment. The primary endpoint is investigator-assessed progression-free survival.</p> Results <p>COPERNICUS is currently enrolling, with a planned enrollment in the United States of 300 and 30 participants in cohorts 1 and 2, respectively, plus 150 participants for cohort&#xa0;1 in Europe.</p> Conclusion <p>COPERNICUS uses a pragmatic study design to evaluate the efficacy and safety of subcutaneous amivantamab regimens combined with advancements in supportive care to prevent and proactively manage AEs in a diverse participant population.</p> <p><MediaObject ID="MOESM1"> <VideoObject FileRef="MediaObjects/40487_2025_386_MOESM1_ESM.mp4" VideoID="-khYwL1Qhkbfz_nXSrB65t"> <Caption Language="En" xml:lang="en"> <CaptionContent> <p>Supplementary file1 (MP4 117333 KB)</p> </CaptionContent> </Caption> </VideoObject> </MediaObject></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月11日

查看全文
  • Balazs Halmos,
  • Narjust Florez,
  • Sarah Goldberg,
  • Wade Iams,
  • Xiuning Le,
  • Ticiana Leal,
  • Danny Nguyen,
  • Luis E. Raez,
  • Jonathan W. Riess,
  • Joshua Sabari,
  • David Bjork,
  • Nichelle Stigger,
  • Yichuan Xia,
  • Paul Cifuentes,
  • Denise D’Andrea,
  • Farah Shanoon,
  • Andy L. Johnson,
  • Melissa L. Johnson

摘要

Introduction

In advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations (Ex19del/L858R), intravenous amivantamab is approved for first-line treatment with lazertinib, and second-line treatment with carboplatin-pemetrexed. Subcutaneous amivantamab demonstrated noninferior pharmacokinetics and comparable efficacy with improved safety outcomes versus intravenous amivantamab in the PALOMA-3 trial. Venous thromboembolism (VTE) was also reduced when combined with prophylactic anticoagulation. In the COCOON trial, an enhanced prophylactic dermatologic regimen with intravenous amivantamab plus lazertinib treatment lowered grade ≥ 2 dermatologic adverse events (AEs). There are no studies combining subcutaneous administration with supportive care advancements in diverse participants with EGFR-mutated NSCLC. COPERNICUS (NCT06667076), an open-label, phase 2b study aims to evaluate the efficacy and safety of subcutaneous amivantamab with lazertinib (cohort 1) or with chemotherapy (cohort 2) while preventing and proactively managing VTE and dermatologic AEs in a multinational, clinically representative population with EGFR-mutated NSCLC.

Methods

Eligible participants are adults with EGFR Ex19del/L858R NSCLC. A pragmatic study approach will be used to eliminate potential barriers to enrollment and increase diversity. Cohort 1 will enroll participants without prior systemic therapy to receive subcutaneous amivantamab and oral lazertinib. Cohort 2 will enroll participants with disease progression on EGFR-tyrosine kinase inhibitors to receive subcutaneous amivantamab and chemotherapy (carboplatin-pemetrexed). Both cohorts will receive enhanced dermatologic management; cohort 1 will receive prophylactic anticoagulation for the first 4 months of treatment. The primary endpoint is investigator-assessed progression-free survival.

Results

COPERNICUS is currently enrolling, with a planned enrollment in the United States of 300 and 30 participants in cohorts 1 and 2, respectively, plus 150 participants for cohort 1 in Europe.

Conclusion

COPERNICUS uses a pragmatic study design to evaluate the efficacy and safety of subcutaneous amivantamab regimens combined with advancements in supportive care to prevent and proactively manage AEs in a diverse participant population.

Supplementary file1 (MP4 117333 KB)